SecBot SecBot
SECBOTREPLAY Home › Report › LLY

LLY · Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage…

Eli Lilly and Company · PRESS-RELEASE filed Sep 11, 2026 at 09:02 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed Sep 11, 2026 at 09:02 ET

Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharma developing neuroplastogens for mental health conditions, including its lead candidate BPL-003 for treatment-resistant depression. The deal expands Lilly's neuroscience pipeline into a novel, rapid-acting therapeutic class for a large unmet need, though no financial terms were disclosed and the assets remain early-stage with clinical and regulatory risk. The acquisition is a strategic pipeline addition for a $1T+ mega-cap, making it a modest positive rather than a transformative event for the stock.

  • Lilly completed the acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company.
  • AtaiBeckley's lead program is BPL-003, a rapid-acting neuroplastogen for treatment-resistant depression.
  • The transaction was approved by AtaiBeckley shareholders at a special meeting prior to closing.
  • No financial terms of the acquisition were disclosed in the press release.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access